Pharma BD Deal Intelligence
Eli Lilly and Company / AC Immune SA
2017 · Licensing/Option · $2.0B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
59
Mixed — partial payoff, real shortfalls.
Lilly licensed AC Immune's anti-tau antibodies for Alzheimer's disease, paying $80M upfront with up to $1.96B in milestones.
Key facts
- Announced Oct 05, 2017
- Deal value $2.0B
- Deal type Licensing/Option
- Therapeutic area Neurology
- Indications Alzheimer's disease
- Key assets Anti-tau antibodies
- Mechanism Anti-tau monoclonal antibody
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals